Valencia, Spain, October 11, 2023 – ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, announced today that it will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023. Company management will participate in virtual one-on-one meetings with potential investors during the conference.
ARTHEx’s lead program, ATX-01, is advancing into clinical development for the treatment of myotonic dystrophy type 1 (DM1), a rare progressive neuromuscular disease.
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact
Frédéric Legros
Executive Chairman and CEO
flegros@arthexbiotech.com
+33679495790
Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
+1 858-366-3243
